Phuturdex › Diseases › Drug Hypersensitivity
Drugs in development · updated 30 October 2026
Drug Hypersensitivity: drugs in development
As of 30 October 2026 there are 3 active clinical trials (recruiting or ongoing, phases I–III) on 17 drugs for drug Hypersensitivity. 0 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Amoxicillinamoxycillin, Moxatag® | III | 1 | NCT06303128 |
| AmpicillinPolycillin-N®, Penbritin-S® | II | 1 | NCT06406114 |
| BenralizumabFasenra® | II | 1 | NCT06734884 |
| CefaclorCeclor Cd®, Ceclor® | II | 1 | NCT06406114 |
| Cefadroxil | II | 1 | NCT06406114 |
| CefdinirOmnicef® | II | 1 | NCT06406114 |
| CefepimeCefepime And Dextrose In Duplex Container®, Cefepime In Plastic Container® | II | 1 | NCT06406114 |
| CefiximeSuprax® | II | 1 | NCT06406114 |
| CefotaximeCefotaxime And Dextrose 2.4% In Plastic Container®, Cefotaxime And Dextrose 3.9% In Plastic Container® | II | 1 | NCT06406114 |
| Cefpodoxime | II | 1 | NCT06406114 |
| CeftazidimeCeftazidime In Dextrose Container®, Ceptaz® | II | 1 | NCT06406114 |
| CeftriaxoneROCEPHIN, Ceftriaxone And Dextrose In Duplex Container® | II | 1 | NCT06406114 |
| CefuroximeCefuroxime And Dextrose In Duplex Container®, Zinacef In Plastic Container® | II | 1 | NCT06406114 |
| CephalexinKeftab®, Keflet® | II | 1 | NCT06406114 |
| Histamine DihydrochlorideCeplene® | II | 1 | NCT06406114 |
Sorted by most advanced phase and number of active trials. Showing 15 of 17 drugs.
All 17 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
Broader categories
- Adverse drug reaction 11 drugs
- Immune System Diseases 54 drugs
- Dermatitis 29 drugs
- Skin disease 34 drugs
- Skin and connective tissue diseases 3 drugs
- Hypersensitivity 22 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D004342 “Drug Hypersensitivity”.